Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma have?
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma has 1,870 citations in the OpenAlex counts ScholarIQ stores.
When was Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma published?
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma has 2018 year in the ScholarIQ index.
What is the open-access status of Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma?
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma has bronze oa status in the ScholarIQ index.
What is the DOI of Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma?
The DOI for Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma is on the source record.
What is the PMID of Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma?
The PMID for Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma is on the source record.
What is the OpenAlex record for Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma?
The OpenAlex for Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma is on the source record.